

Global Multiple Sclerosis Therapeutic Market Size study, by Drug Class (Immunosuppressants, Immunostimulants, Immunomodulators), Route of Administration (Oral, Injectable [Intramuscular, Intravenous]), Distribution Channel (Hospital, Retail, Online), and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G20E0714E7B3EN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,218.00 (Single User License)

ID: G20E0714E7B3EN

Abstracts

The Global Multiple Sclerosis Therapeutic Market is valued at approximately USD 25.5 billion in 2023 and is projected to grow at a healthy compound annual growth rate of more than 4.70% over the forecast period from 2024 to 2032. Multiple sclerosis (MS), a chronic and progressive autoimmune neurological disorder affecting the central nervous system, continues to burden healthcare systems globally due to its complex pathology and long-term disability implications. In response, the therapeutic landscape has undergone a fundamental shift, propelled by a surge in precision medicine approaches and the launch of innovative disease-modifying therapies (DMTs). From early-stage relapsing-remitting MS to more severe progressive forms, the focus has moved toward immunomodulatory regimens designed to delay disease progression, reduce relapse rates, and preserve patient quality of life.

Market momentum is being shaped by several key forces. Advancements in immunology and biotechnology have catalyzed the development of highly specific monoclonal antibodies, next-gen oral agents, and biosimilars that enhance therapeutic effectiveness while minimizing adverse effects. The escalating prevalence of MS in developed economies, aligned with rising disease awareness and improvements in diagnostic imaging technologies like MRI, has widened the treated population base. In parallel, strategic collaborations among biopharmaceutical firms and academic institutes are streamlining clinical pipelines and accelerating regulatory approvals, while emerging

digital therapeutics and AI-based patient management tools are setting the stage for personalized treatment pathways that enhance patient compliance and long-term monitoring.

However, systemic constraints continue to temper market acceleration. Chief among them is the high cost associated with premium biologics and patented DMTs, which can significantly burden healthcare budgets and insurance frameworks—especially in emerging markets. In addition, variability in drug response and patient adherence, compounded by treatment side effects and therapeutic resistance, poses significant challenges. Despite these headwinds, the market outlook remains optimistic due to the introduction of novel oral therapies and the growing emphasis on combination treatment strategies that bridge efficacy gaps between relapsing and progressive MS subtypes.

Geographically, North America holds the lion's share of the global MS therapeutics market, underpinned by advanced healthcare infrastructure, substantial R&D investments, and supportive reimbursement environments. The United States leads with early drug adoption and a high concentration of market players and neurologists specializing in MS care. Europe follows closely, driven by centralized disease registries, proactive policy frameworks, and universal healthcare systems in nations such as Germany, the UK, and France. Asia Pacific, meanwhile, is poised to witness the fastest growth through 2032, catalyzed by increasing MS incidence, rising healthcare expenditure, and regulatory reforms facilitating faster drug access in countries like India and China. Latin America and the Middle East & Africa are also gradually emerging as focal regions, thanks to international funding support, government awareness programs, and improving neurology services.

Major market player included in this report are:

Biogen Inc.

Merck & Co., Inc.

Sanofi S.A.

F. Hoffmann-La Roche Ltd

Novartis AG

Pfizer Inc.

Teva Pharmaceutical Industries Ltd.

Bristol-Myers Squibb Company

Johnson & Johnson

GlaxoSmithKline plc

Bayer AG

AbbVie Inc.

Amgen Inc.

AstraZeneca PLC

Takeda Pharmaceutical Company Limited

The detailed segments and sub-segment of the market are explained below:

By Drug Class

Immunosuppressants

Immunostimulants

Immunomodulators

By Route of Administration

Oral

Injectable

Intramuscular

Intravenous

By Distribution Channel

Hospital

Retail

Online

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Global Multiple Sclerosis Therapeutic Market Size study, by Drug Class (Immunosuppressants, Immunostimulants,...

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Contents

CHAPTER 1. GLOBAL MULTIPLE SCLEROSIS THERAPEUTIC MARKET EXECUTIVE SUMMARY

- 1.1. Global Multiple Sclerosis Therapeutic Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Drug Class
 - 1.3.2. By Route of Administration
 - 1.3.3. By Distribution Channel
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL MULTIPLE SCLEROSIS THERAPEUTIC MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Payer & Patient Perspectives)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Diagnostic Imaging Advances
 - 2.3.4.2. Patient Awareness & Support Programs
 - 2.3.4.3. Technology-Enabled Disease Management
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
 - Historical year – 2022
 - Base year – 2023
 - Forecast period – 2024 to 2032
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL MULTIPLE SCLEROSIS THERAPEUTIC MARKET DYNAMICS

3.1. Market Drivers

- 3.1.1. Rising MS Prevalence and Improved Diagnosis
- 3.1.2. Launch of Next-Generation Disease-Modifying Therapies
- 3.1.3. Strategic Collaborations and R&D Investment

3.2. Market Challenges

- 3.2.1. High Cost of Biologics and Access Barriers
- 3.2.2. Variability in Patient Response and Adherence
- 3.2.3. Side-Effect Management and Safety Concerns

3.3. Market Opportunities

- 3.3.1. Growth of Biosimilars and Oral Agents
- 3.3.2. Integration of Digital Therapeutics and AI Tools
- 3.3.3. Expansion in Emerging Markets

CHAPTER 4. GLOBAL MULTIPLE SCLEROSIS THERAPEUTIC MARKET INDUSTRY ANALYSIS

4.1. Porter's Five Forces Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's Model
- 4.1.7. Porter's Impact Analysis

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunities

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspective

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE & FORECASTS BY DRUG CLASS 2022–2032

5.1. Segment Dashboard

5.2. Global Market: Drug Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)

5.2.1. Immunosuppressants

5.2.2. Immunostimulants

5.2.3. Immunomodulators

CHAPTER 6. GLOBAL MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE & FORECASTS BY ROUTE OF ADMINISTRATION 2022–2032

6.1. Segment Dashboard

6.2. Global Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)

6.2.1. Oral

6.2.2. Injectable

– Intramuscular

– Intravenous

CHAPTER 7. GLOBAL MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE & FORECASTS BY DISTRIBUTION CHANNEL 2022–2032

7.1. Segment Dashboard

7.2. Global Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)

7.2.1. Hospital

7.2.2. Retail

7.2.3. Online

CHAPTER 8. GLOBAL MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE & FORECASTS BY REGION 2022–2032

8.1. North America

8.1.1. U.S.

8.1.1.1. Drug Class breakdown, 2022–2032

8.1.1.2. Route of Administration breakdown, 2022–2032

- 8.1.2. Canada
- 8.2. Europe
 - 8.2.1. UK
 - 8.2.2. Germany
 - 8.2.3. France
 - 8.2.4. Spain
 - 8.2.5. Italy
 - 8.2.6. Rest of Europe
- 8.3. Asia Pacific
 - 8.3.1. China
 - 8.3.2. India
 - 8.3.3. Japan
 - 8.3.4. Australia
 - 8.3.5. South Korea
 - 8.3.6. Rest of Asia Pacific
- 8.4. Latin America
 - 8.4.1. Brazil
 - 8.4.2. Mexico
 - 8.4.3. Rest of Latin America
- 8.5. Middle East & Africa
 - 8.5.1. Saudi Arabia
 - 8.5.2. South Africa
 - 8.5.3. Rest of Middle East & Africa

CHAPTER 9. COMPETITIVE INTELLIGENCE

- 9.1. Key Company SWOT Analysis
 - 9.1.1. Biogen Inc.
 - 9.1.2. Merck & Co., Inc.
 - 9.1.3. Sanofi S.A.
- 9.2. Top Market Strategies
- 9.3. Company Profiles
 - 9.3.1. Biogen Inc.
 - 9.3.1.1. Key Information
 - 9.3.1.2. Overview
 - 9.3.1.3. Financial (Subject to Data Availability)
 - 9.3.1.4. Product Summary
 - 9.3.1.5. Market Strategies
 - 9.3.2. Merck & Co., Inc.

- 9.3.3. Sanofi S.A.
- 9.3.4. F. Hoffmann-La Roche Ltd
- 9.3.5. Novartis AG
- 9.3.6. Pfizer Inc.
- 9.3.7. Teva Pharmaceutical Industries Ltd.
- 9.3.8. Bristol-Myers Squibb Company
- 9.3.9. Johnson & Johnson
- 9.3.10. GlaxoSmithKline plc
- 9.3.11. Bayer AG
- 9.3.12. AbbVie Inc.
- 9.3.13. Amgen Inc.
- 9.3.14. AstraZeneca PLC
- 9.3.15. Takeda Pharmaceutical Company Limited

CHAPTER 10. RESEARCH PROCESS

- 10.1. Research Process
 - 10.1.1. Data Mining
 - 10.1.2. Analysis
 - 10.1.3. Market Estimation
 - 10.1.4. Validation
 - 10.1.5. Publishing
- 10.2. Research Attributes

I would like to order

Product name: Global Multiple Sclerosis Therapeutic Market Size study, by Drug Class (Immunosuppressants, Immunostimulants, Immunomodulators), Route of Administration (Oral, Injectable [Intramuscular, Intravenous]), Distribution Channel (Hospital, Retail, Online), and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G20E0714E7B3EN.html>

Price: US\$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G20E0714E7B3EN.html>